Advertisement
Advertisement


News Briefs

Herpes Vaccine Trial Needs 7,500 Women

November 26, 2002


This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

For a new vaccine trial, the National Institute of Allergy and Infectious Diseases is working with GlaxoSmithKline to find a rare population of women -- those who have never been infected with genital herpes or the cold sore virus, both of which are incredibly common. Researchers hope the new vaccine will win approval based on the trial's results. "More than 1 million new cases of genital herpes are diagnosed in the United States each year," NIAID Director Dr. Anthony Fauci said last week. The trial was set up just a day after researchers confirmed the vaccine can prevent up to 70 percent of genital herpes infections among women; it does not seem to work for men, however. For more information about the trial, visit www.niaid.nih.gov/dmid/stds/herpevac/.

Back to other CDC news for November 26, 2002

Previous Updates

Adapted from:
Detroit Free Press
11.26.02




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
What Did You Expect While You Were Expecting?
HIV/AIDS Resource Center for Women

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.